Revue des Maladies Respiratoires, Journal Year: 2022, Volume and Issue: 39(8), P. 685 - 697
Published: Aug. 30, 2022
Language: Английский
Physician Assistant Clinics, Journal Year: 2023, Volume and Issue: 8(4), P. 739 - 747
Published: July 14, 2023
Language: Английский
Citations
0
Published: Jan. 1, 2023
Background: Respiratory symptoms affect half of Europe's adult population and are associated with increased health burden. We aimed to identify respiratory symptom clusters assess their associations all-cause cause-specific mortality.Methods: Questionnaire data from two Swedish population-representative cohorts (N=63,060; baseline age 16-75 years) up 21 years linked mortality register (>600,000 person 3,576 recorded deaths) were used. Cluster analysis, based on the presence/absence symptoms, was performed in subjects reporting at least one symptom. Associations evaluated using asymptomatic as reference.Findings: Seven identified: 1) "low-symptomatic"; 2) "allergic nasal symptoms"; 3) wheezing, dyspnea attacks"; 4) "recurrent productive cough, allergic 5) cough non-allergic 6) "wheezing 7) "chronic dyspnea, recurrent wheezing". The differed by sex, smoking status, disease, allergy, comorbidity All except cluster 2 outcome. In general, all-cause, respiratory, cardiovascular chronicity number reported symptoms.Interpretation: different expression could be derived a broad population-based which differentially mortality.Funding: Research Council, Avtal om Läkarutbildning och Forskning (ALF; regional agreements between Umeå University Region Norrbotten Gothenburg Västra Götaland), Council for Health, Working Life Welfare (Forte), Heart-Lung foundation, Hermann Krefting Foundation, Kamprad Family Nordic Asthma & Allergy Foundation.Declaration Interest: Helena Backman reports personal fees AstraZeneca, Boehringer-Ingelheim, GSK, outside current work. Hannu Kankaanranta lectures consulting Chiesi Pharma, MSD, Novartis, Orion Sanofi Genzyme Fredrik Nyberg holds some AstraZeneca shares. Anne Lindberg advisory board work GlaxoSmithKline, Novartis Boehringer Ingelheim, well scientific Ingelheim both submitted other authors declare no conflict interest relation this Lowie E.G.W. Vanfleteren lectures, or Chiesi, Pulmonx.Ethical Approval: study approved Regional Ethical Board National Review Authority.
Language: Английский
Citations
0
Polski Merkuriusz Lekarski, Journal Year: 2023, Volume and Issue: 51(4), P. 314 - 320
Published: Jan. 1, 2023
Aim: To analyze the effectiveness of rehabilitation treatment in conditions halo aerosol therapy and when using different groups fixed-dose inhalers patients with asthma, chronic obstructive pulmonary diseases asthma-chronic overlap.Materials Methods: A total 112 overlap. All carefully collected allergic history, anamnesis life, disease. The study includes assessment resting anthropometric data, physical activity habits, blood pressure, structure quality nutrition, family economic data.Result: After a course treatment, lung ventilation improved all compared to controls. dynamics FER indicators after had some differences for each group relation control groups. If (control) increase was insignificant, then B it significant, differed from 14,6% up 36%.Conclusions: Thus, differentiated approach use increases under various genesis bronchi-obstructive syndrome.
Language: Английский
Citations
0
Revue des Maladies Respiratoires, Journal Year: 2022, Volume and Issue: 39(8), P. 685 - 697
Published: Aug. 30, 2022
Language: Английский
Citations
0